Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

How Fast Is The Breast Cancer Liquid Biopsy Market Expected to Grow Between 2025 And 2029?

Rapid expansion has been seen in the breast cancer liquid biopsy market size in the past few years. The market is projected to escalate from $0.78 billion in 2024 to $0.90 billion in 2025, reflecting a compound annual growth rate (CAGR) of 15.0%. The historical period growth is mainly due to the progression in next-generation sequencing (ngs), escalating instances of breast cancer, growing inclination for non-invasive diagnostic procedures, increasing adoption of personalized medical approaches, and augmented funds directed towards cancer research.

The market size of breast cancer liquid biopsy is predicted to experience significant growth in the upcoming years, expanding to $1.56 billion by 2029 at a Compound Annual Growth Rate (CAGR) of 14.7%. This surge during the forecasted timeframe can be ascribed to the evolution in liquid biopsy assays technology, the growing utilization of liquid biopsy for early cancer detection, increasing need for real-time cancer monitoring, broadening features in precision oncology, and increase in investments for liquid biopsy research and development. Major forecasted trends include the incorporation of artificial intelligence in liquid biopsy examination, enhancements in single-cell sequencing, creation of multi-omics liquid biopsy platforms, enhancement in liquid biopsy specificity and sensitivity, and the adoption of digital PCR for ultra-precise mutation identification.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21119&type=smp

Which Primay Drivers Are Accelerating Growth in the Breast Cancer Liquid Biopsy Market?

The growth of the breast cancer liquid biopsy market is predicted to be driven by the escalation in breast cancer incidents. Breast cancer emerges from breast cells, predominantly from the lobules (milk-producing glands) or ducts (channels that transport milk to the nipple). The surge in breast cancer is attributable to several factors, including genetic predisposition, hormonal imbalances, an aging population, lifestyle alterations, obesity, alcohol usage, insufficient physical activity, exposure to radiation, and environmental pollutants. A liquid biopsy for breast cancer aids in the treatment by identifying circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the blood, which helps in monitoring the disease in real-time. This procedure contributes to gauging the response to treatment, detecting resistance to therapy, and pinpointing genetic mutations for targeted treatments. To illustrate, the American Cancer Society, a US-based charitable organisation know for its work in cancer research, education, advocacy, and patient support, predict an escalation in new breast cancer incidences to 319,750 in 2025, a substantial rise from 313,510 cases in 2024. Thus, the rise in breast cancer cases fuels the expansion of the liquid biopsy market for breast cancer.

Which Primary Segments of the Breast Cancer Liquid Biopsy Market Are Driving Growth and Industry Transformations?

The breast cancer liquid biopsy market covered in this report is segmented –

1) By Product: Consumables, Kits

2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers

3) By Application: Early Detection Or Screening, Diagnosis, Other Applications

4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories

Subsegments:

1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes

2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21119&type=smp

Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Breast Cancer Liquid Biopsy Market?# Market?

North America was the largest region in the breast cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Technological Trends Are Reshaping the Breast Cancer Liquid Biopsy Industry Dynamics?

A primary focus of leading businesses in the breast cancer liquid biopsy market is on the creation of innovative products like companion diagnostics, facilitating bespoke treatment strategies through the identification of patients who will gain from specific treatments. These companion diagnostics employ liquid biopsy technologies to identify biomarkers such as genetic alterations, circulating tumor DNA (ctDNA), or expressions of proteins that signal responsiveness to treatment. For instance, in January 2023, the FDA approved Guardant Health Inc., a biotechnology firm based in the US, for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Menarini Group’s ORSERDU (elacestrant), which is a treatment for patients with advanced or metastatic breast cancer carrying ESR1 mutations. This approval empowers oncologists to use the test for wide-ranging genomic profiling, pinpointing patients who might profit from targeted treatment. This represents Guardant Health’s first FDA approval for breast cancer, and broadens its involvement in precision oncology.

View the full report here:

https://www.thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report

What Parameters Are Used to Define the Breast Cancer Liquid Biopsy Market?

A breast cancer liquid biopsy is a minimally invasive test that detects and analyzes tumor-derived materials in a patient’s blood or other bodily fluids. It provides valuable insights into the presence, progression, and genetic profile of breast cancer without requiring a traditional tissue biopsy.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21119

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model